/Investor DB

Cambridge Innovation Capital — 2022 Investments

7 investments dated 2022 · listed companies and verified rows first · show all

Pretzel Therapeuticspretzeltx.cominSeries A · Sep 2022 · $73M✓ verified

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.

BiotechDeep TechHealthtechMedical Devices

Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)

Co-investorsARCH Venture PartnersEIR VenturesAngelini VenturesGU Ventures ABGV (Google Ventures)HealthCap+3 more

Cambridge GaN Devicescamgandevices.comin𝕏Series B · Nov 2022 · $19M

Cambridge GaN Devices is a fabless semiconductor company that develops energy-efficient GaN-based power devices for sustainable electronics.

CleantechDeep TechEnergyHardwareSemiconductorsCambridge, GB

Fabio Necco(CEO)in

Co-investorsEMV CapitalIQ CapitalMartlet CapitalBritish Patient CapitalBusiness Growth FundePlanet Capital+1 more

Carrick Therapeuticscarricktherapeutics.cominDec 2022

Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Timothy Pearson(CEO)Ash Bahl(CSO)inJenny Horsfield(CBO)inStuart McIntosh(CMO)inDavid Sutherland(VP Finance & Controller)

Co-investorsARCH Venture PartnersB Capital GroupB4 CapitalGV (Google Ventures)Lightstone VenturesRevelation Partners+2 more

Microbioticamicrobiotica.cominSeries B · Feb 2022 · $68M

Microbiotica is a clinical-stage biopharmaceutical company developing precision live biotherapeutic products derived from the human microbiome for immuno-oncology and inflammatory bowel disease.

BiotechDigital HealthHealthtechMedical DevicesCambridge, GB

Trevor Lawley(Co-founder and CSO)in

Co-investorsSeventure PartnersDCVC (Data Collective)IP Group

Nucleranuclera.cominSeries B · Jul 2022 · $16M

Nuclera provides multiplex protein screening technology for life science researchers, enabling faster access to and testing of proteins for drug discovery and development.

AI & Machine LearningBiotechDeep TechHardwareCambridge, US

Co-investorsBritish Business BankAmadeus Capital PartnersFuture Planet Capital

UnlikelyAIunlikely.aiinSeed · Sep 2022 · $20M

UnlikelyAI builds AI technology designed to support real-world decision-making through interpretable and trustworthy models.

AI & Machine LearningEnterprise Software

Co-investorsAmadeus Capital PartnersCambridge Angels groupMetaplanetMS&AD VenturesOctopus Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Botanical Ventures Limited

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.